2.72Open2.72Pre Close0 Volume2 Open Interest1.50Strike Price0.00Turnover854.66%IV1.20%PremiumDec 20, 2024Expiry Date2.67Intrinsic Value100Multiplier23DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.9392Delta0.0135Gamma1.19Leverage Ratio-0.0241Theta0.0003Rho1.12Eff Leverage0.0013Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet